SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Discussion centers on the Phase 3 REGAL AML trials final-analysis trigger: the last disclosed count was 78 of 80 death events, leaving traders focused on when SELLAS will confirm the 80th event and share results, amid debate over its prolonged silence and speculation about an ASH embargo. Bulls interpret the extended timeline as a possible sign of longer survival, while skeptics question the delay and trial design; options-related volatility and broader biotech weakness are secondary concerns.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius is being swept into a sharp selloff across AI neocloud and data-center stocks as investors reassess the sectors debt-funded growth, financing costs, and ability to earn returns on heavy infrastructure spending. Traders are split between viewing the decline as an oversold, sector-wide repricing and warning that debt and profitability risks could drive further losses.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

A sharp futures rebound after a bruising week, ahead of major tech earnings, has put SPY in focus amid chatter about the 1987 Black Monday anniversary. Traders are split on whether the move signals a durable recovery or a short-covering bounce that could fade at the open.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovances ESMO data are driving discussion, particularly mature frontline melanoma results for lifileucel plus pembrolizumab showing durable responses and a median progression-free survival of 19.8 months, alongside preliminary sarcoma results. Many traders view the data as supportive of expansion potential, while others stress the small study sizes and say the abstracts largely confirm earlier findings; some attribute the share-price weakness to broader biotech selling rather than a company-specific setback.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Concern over Cerebras IPO lockup releases and newly eligible shares is a dominant topic, with traders debating whether added supply is driving the steep decline; broader weakness in AI and semiconductor stocks and questions about the companys valuation are adding pressure. Bears see room for further losses, while some investors view the selloff as an oversold buying opportunity and remain bullish on Cerebras AI-inference technology.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

A sharp futures rebound after a bruising tech selloff is driving QQQ discussion, alongside fears tied to the Black Monday anniversary. Traders are split on whether the bounce marks a durable recovery ahead of major tech earnings or a short-covering rally that could fade, with AI-sector concerns still weighing on sentiment.

Cipher Digital, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Digital Inc.

Ciphers convertible-note offering has intensified concerns about dilution and financing risk, amid a broader selloff in AI data-center and mining stocks as investors reassess debt costs and sector prospects. Traders are divided between bearish concerns about management, leverage and continued declines and bullish hopes that the pullback is overdone given long-term AI infrastructure demand.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: QNX, Secure Communications, and Licensing. The QNX segment includes development of safe and reliable software for embedded systems across technology-driven industries. The Secure Communications segment delivers operational resiliency with a government-grade portfolio of secure, certified solutions for mobile fortification, critical communications and crisis management. The Licensing segment focuses on management and monetization of the firm's global patent portfolio. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is drawing attention for QNX momentum, especially the first Alloy Kore vehicle-platform design win and hopes for more automotive and physical-AI adoption; traders also cite a recent earnings beat and raised outlook. Bullish investors see the deals and backlog as evidence of future growth, while skeptics question how quickly design wins will translate into revenue and whether the share price reflects that potential.

iShares Trust - iShares Semiconductor ETF

iShares Semiconductor ETF

A prolonged semiconductor selloff has put SOXX in focus, with traders debating whether doubts about AI spending returns, inflation and crowded positioning point to a deeper correction or an oversold bounce. Bears warn the AI trade may be unwinding, while bulls argue chip demand remains strong and the pullback could be temporary.

SPDR Series Trust - State Street SPDR S&P Biotech ETF

SPDR S&P Biotech ETF

XBI is drawing attention amid a broad biotech selloff that traders link to rising yields, rate concerns, and rotation away from riskier small-cap names toward AI and other sectors. The community is split between viewing the decline as an oversold buying opportunity and warning that technical weakness and macro pressure could drive further losses.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$GOOGL: $40 to $200 is the court estimate in the Google Play kids&#39; privacy case, based on just 1% to 2% of 3.8M to 10M kids filing. Filed claims are in, approval is still pending. Claims closed. Open Class Actions.

StockTwits Web

Alphabet Inc Class A

: $40 to $200 is the court estimate in the Google Play kids' privacy case, based on just 1% to 2% of 3.8M to 10M kids filing. Filed claims are in, approval is still pending. Claims closed. Open Class Actions.